

stress-testing information across institutions. The change also would ensure that future collections of this information remain uniform across the agencies.

With OMB approval, the first annual filing deadline for the FFIEC 016 report form would be July 31, 2018, using information as of December 31, 2017.

II. Request for Comment

Public comment is requested on all aspects of this joint notice. Comments are specifically invited on:

(a) Whether the collections of information that are the subject of this notice are necessary for the proper performance of the agencies' functions, including whether the information has practical utility;

(b) The accuracy of the agencies' estimates of the burden of the information collections as they are proposed to be revised, including the validity of the methodology and assumptions used;

(c) Ways to enhance the quality, utility, and clarity of the information to be collected;

(d) Ways to minimize the burden of information collections on respondents, including through the use of automated collection techniques or other forms of information technology; and

(e) Estimates of capital or start-up costs and costs of operation, maintenance, and purchase of services to provide the information.

Comments submitted in response to the joint notice will be shared among the agencies. All comments will become a matter of public record.

Dated: February 15, 2018.

Karen Solomon,

Acting Senior Deputy Comptroller and Chief Counsel, Office of the Comptroller of the Currency.

Board of Governors of the Federal Reserve System, February 12, 2018.

Ann E. Misback,

Secretary of the Board.

Dated at Washington, DC, on February 12, 2018.

Federal Deposit Insurance Corporation.

Robert E. Feldman,

Executive Secretary.

[FR Doc. 2018-03736 Filed 2-22-18; 8:45 am]

BILLING CODE 4810-33-P; 6210-01-P; 6714-01-P

DEPARTMENT OF VETERANS AFFAIRS

Tiered Pharmacy Copayments for Medications Update

AGENCY: Department of Veterans Affairs.

ACTION: Notice.

SUMMARY: This Department of Veterans Affairs (VA) notice updates the information on Tier 1 medications.

FOR FURTHER INFORMATION CONTACT: Joseph Duran, Office of Community Care (10D), Veterans Health Administration (VHA), Department of Veterans Affairs, 810 Vermont Avenue NW, Washington, DC 20420, *Joseph.Duran2@va.gov*, (303) 372-4629 (this is not a toll free number).

SUPPLEMENTARY INFORMATION: Section 17.110 of Title 38, Code of Federal Regulations, governs copayments for medications that VA provides to

veterans. Section 17.110 provides the methodologies for establishing the copayment amount for each 30-day or less supply of medication provided by VA on an outpatient basis (other than medication administered during treatment). "Tier 1 medication means a multi-source medication that has been identified using the process described in paragraph (b)(2) of this section."

Section 17.110 provides that a list of Tier 1 medications will either be published as a notice in the **Federal Register** or will be posted on VA's website at *www.va.gov/health* at least once per year.

Based on the methodologies set forth in § 17.110, this notice updates the list of Tier 1 medications. Not less than once per year, VA will identify a subset of multi-source medications as Tier 1 medications. Only medications that meet all of the criteria in paragraphs (b)(2)(i), (ii), and (iii) will be eligible to be considered Tier 1 medications, and only those medications that meet all of the criteria in paragraph (b)(2)(i) of this section will be assessed using the criteria in paragraphs (b)(2)(ii) and (iii). As of the date of this notice, the Tier 1 medication list at individual VA medical facilities based on the methodologies in § 17.110 will be posted on VA's website at *www.va.gov/health* under the heading "Tier 1 Copay Medication List."

The following table is the Tier 1 Copay Medication List that is effective January 1, 2018, and will remain in effect until December 31, 2018.

Condition	VA product name
Arthritis & Pain	Aspirin buffered tablet. Aspirin chewable tablet. Aspirin enteric coated tablet. Allopurinol tablet. Diclofenac Sodium EC tablet. Ibuprofen tablet. Meloxicam tablet. Naproxen tablet.
Blood Thinners & Platelet Inhibitors.	Clopidogrel Bisulfate tablet. Warfarin Sodium tablet.
Bone Health	Alendronate tablet.
Cholesterol	Atorvastatin tablet. Gemfibrozil tablet. Lovastatin tablet. Niacin (Slo-Niacin) tablet. Pravastatin tablet. Simvastatin tablet.
Dementia	Donepezil tablet.
Diabetes	Glipizide tablet. Metformin HCL tablet. Metformin HCL 24hr (SA) tablet.
Electrolyte Supplement	Potassium SA tablet. Potassium SA Dispersible tablet.
Gastrointestinal Health	Omeprazole EC capsule. Pantoprazole Sodium EC capsule. Ranitidine tablet.

Condition	VA product name
Glaucoma & Eye Care	Brimonidine 0.2% solution. Dorzolamide 2%/Timolol 0.5% sol. Latanoprost 0.005% solution.
Heart Health & Blood Pressure	Amlodipine tablet. Aspirin (see Arthritis & Pain). Atenolol tablet. Carvedilol tablet. Chlorthalidone tablet. Clonidine tablet. Digoxin tablet. Diltiazem 24HR capsule. Diltiazem HCL tablet. Enalapril Maleate tablet. Furosemide tablet. Hydralazine HCL tablet. Hydrochlorothiazide tablet/capsule. Hydrochlorothiazide/Lisinopril tablet. Hydrochlorothiazide/Triamterene cap/tab. Isosorbide Mononitrate SA tablet. Lisinopril tablet. Losartan tablet. Metoprolol Succinate SA tablet. Metoprolol Tartrate tablet. Nifedipine SA capsule. Nitroglycerin sublingual tablet. Prazosin HCL capsule. Propranolol HCL tablet. Spironolactone tablet. Valsartan tablet. Verapamil HCL tablet. Verapamil HCL SA tablet.
Mental Health	Bupropion HCL tablet. Bupropion HCL SA (12HR–SR) tablet. Bupropion HCL SA (24HR–XL) tablet. Buspirone HCL tablet. Citalopram Hydrobromide tablet. Duloxetine HCL EC capsule. Escitalopram Oxalate tablet. Fluoxetine capsule/tablets. Mirtazapine tablet. Paroxetine HCL tablet. Quetiapine Fumarate tablet. Risperidone tablet. Risperidone tablet, disintegrating. Sertraline HCL tablet. Trazodone tablet. Venlafaxine HCL tablet. Venlafaxine HCL SA tablet/cap.
Parkinson Diseases/Restless Legs Syndrome	Carbidopa/Levodopa tablet.
Seizures	Gabapentin capsule. Lamotrigine tablet. Topiramate tablet.
Thyroid Conditions	Levothyroxine Sodium tablet.
Urologic (Bladder & Prostate) Health.	Alfuzosin HCL SA tablet. Doxazosin Mesylate tablet. Finasteride tablet. Oxybutynin Chloride tablet. Oxybutynin Chloride SA tablet. Tamsulosin HCL capsule. Terazosin HCL capsule.

Signing Authority

The Secretary of Veterans Affairs, or designee, approved this document and authorized the undersigned to sign and submit the document to the Office of the Federal Register for publication electronically as an official document of the Department of Veterans Affairs. Gina S. Farrissee, Deputy Chief of Staff,

Department of Veterans Affairs,
approved this document on February
12, 2018, for publication.

Dated: February 12, 2018.

Jeffrey Martin,

*Impact Analyst, Office of Regulation Policy
& Management, Office of the Secretary,
Department of Veterans Affairs.*

[FR Doc. 2018–03724 Filed 2–22–18; 8:45 am]

BILLING CODE 8320–01–P